| Public shareholders 172 companies · $119494.4B | 172 companies | $119494.4B | Oncology |
| Institutional investors 27 companies · $8758.4B | 27 companies | $8758.4B | Oncology |
| Public shareholders via NSE listing 2 companies · $1511.3B | 2 companies | $1511.3B | Diabetes |
| Promoter group 2 companies · $1365.8B | 2 companies | $1365.8B | Cardiovascular |
| Institutional investors including Vanguard, BlackRock, State Street 2 companies · $843.0B | 2 companies | $843.0B | Oncology |
| Public market investors 16 companies · $795.2B | 16 companies | $795.2B | Oncology |
| BlackRock 4 companies · $675.4B | 4 companies | $675.4B | Oncology |
| Serum Institute of India 2 companies · $616.9B | 2 companies | $616.9B | Diabetes |
| Foreign Institutional Investors (FIIs) 2 companies · $406.4B | 2 companies | $406.4B | Cardiovascular |
| Mutual funds 2 companies · $396.4B | 2 companies | $396.4B | Cardiovascular |
| Public shareholders via Hong Kong Stock Exchange 2 companies · $208.8B | 2 companies | $208.8B | Oncology |
| Retail investors 3 companies · $166.7B | 3 companies | $166.7B | Oncology |
| Public shareholders via HKEX listing 2 companies · $165.6B | 2 companies | $165.6B | Oncology |
| Public shareholders via Shenzhen Stock Exchange 2 companies · $113.0B | 2 companies | $113.0B | Cardiovascular |
| Vanguard 2 companies · $105.6B | 2 companies | $105.6B | Oncology |
| Flagship Pioneering 3 companies · $21.9B | 3 companies | $21.9B | Oncology |
| Arch Venture Partners 11 companies · $16.1B | 11 companies | $16.1B | Oncology |
| Atlas Venture 9 companies · $14.7B | 9 companies | $14.7B | Oncology |
| Venrock 6 companies · $12.6B | 6 companies | $12.6B | Neurology |
| RA Capital Management 11 companies · $11.7B | 11 companies | $11.7B | Oncology |
| Third Rock Ventures 7 companies · $11.1B | 7 companies | $11.1B | Oncology |
| Institut Mérieux (majority shareholder) 2 companies · $10.9B | 2 companies | $10.9B | Infectious Diseases |
| Fidelity 4 companies · $10.2B | 4 companies | $10.2B | Oncology |
| Fairmount Funds Management LLC 2 companies · $10.0B | 2 companies | $10.0B | Oncology |
| BVF Partners 4 companies · $9.8B | 4 companies | $9.8B | Metabolic Diseases |
| Medicxi 4 companies · $8.5B | 4 companies | $8.5B | Oncology |
| Foresite Capital 3 companies · $7.0B | 3 companies | $7.0B | Oncology |
| Other institutional and public shareholders 3 companies · $6.9B | 3 companies | $6.9B | Oncology |
| EcoR1 Capital 2 companies · $6.6B | 2 companies | $6.6B | Oncology |
| Frazier Healthcare Partners 2 companies · $6.6B | 2 companies | $6.6B | Rare Liver Diseases |
| Longitude Capital 3 companies · $6.6B | 3 companies | $6.6B | Oncology |
| Samsara BioCapital 5 companies · $6.2B | 5 companies | $6.2B | Nephrology |
| Casdin Capital 3 companies · $6.1B | 3 companies | $6.1B | Rare Diseases |
| Public shareholders via NASDAQ 2 companies · $6.0B | 2 companies | $6.0B | Rare Diseases |
| Other institutional investors 4 companies · $6.0B | 4 companies | $6.0B | Oncology |
| Baker Bros. Advisors 4 companies · $5.6B | 4 companies | $5.6B | Oncology |
| Pfizer 4 companies · $5.6B | 4 companies | $5.6B | Oncology |
| Deerfield Management 2 companies · $5.4B | 2 companies | $5.4B | Cardiovascular |
| Fidelity Management & Research Company 5 companies · $4.9B | 5 companies | $4.9B | Oncology |
| Vertex Pharmaceuticals 2 companies · $4.9B | 2 companies | $4.9B | Hemoglobinopathies |
| Roivant Sciences 2 companies · $4.7B | 2 companies | $4.7B | Immunology |
| Forbion 4 companies · $4.3B | 4 companies | $4.3B | Cardiovascular |
| The Column Group 2 companies · $3.8B | 2 companies | $3.8B | Neurodegenerative Diseases |
| OrbiMed 4 companies · $3.1B | 4 companies | $3.1B | Immunology |
| Bain Capital Life Sciences 2 companies · $3.1B | 2 companies | $3.1B | Oncology |
| Sanofi 2 companies · $3.1B | 2 companies | $3.1B | Infectious Disease |
| Institutional and public shareholders 3 companies · $2.8B | 3 companies | $2.8B | Oncology |
| New Enterprise Associates (NEA) 4 companies · $2.7B | 4 companies | $2.7B | Neuroscience |
| Wellington Management 2 companies · $2.5B | 2 companies | $2.5B | Oncology |
| GV (Google Ventures) 2 companies · $2.5B | 2 companies | $2.5B | Rare Diseases |
| Oberland Capital 2 companies · $2.4B | 2 companies | $2.4B | Ophthalmology |
| Peter Thiel 2 companies · $2.3B | 2 companies | $2.3B | Neuroscience |
| Other institutional public market investors 2 companies · $2.1B | 2 companies | $2.1B | Oncology |
| Gilead Sciences 2 companies · $2.0B | 2 companies | $2.0B | Immunology |
| Cormorant Asset Management 2 companies · $1.9B | 2 companies | $1.9B | Oncology |
| Perceptive Advisors 3 companies · $1.8B | 3 companies | $1.8B | Oncology |
| Public Shareholders (WSE) 2 companies · $1.7B | 2 companies | $1.7B | Oncology |
| Catalio Capital Management 2 companies · $1.7B | 2 companies | $1.7B | Psychiatry |
| Versant Ventures 2 companies · $1.5B | 2 companies | $1.5B | Oncology |
| Pontifax 3 companies · $1.5B | 3 companies | $1.5B | Oncology |
| Kleiner Perkins 3 companies · $1.4B | 3 companies | $1.4B | Neuropsychiatry |
| Westlake Village BioPartners 3 companies · $1.4B | 3 companies | $1.4B | Autoimmune Diseases |
| Redmile Group 3 companies · $1.2B | 3 companies | $1.2B | Neuropsychiatry |
| Polaris Partners 4 companies · $1.2B | 4 companies | $1.2B | Neurology |
| Public Shareholders (Euronext Paris, Nasdaq) 2 companies · $1.1B | 2 companies | $1.1B | Infectious Diseases |
| Boxer Capital 2 companies · $1.1B | 2 companies | $1.1B | Neurology |
| F-Prime Capital 2 companies · $909.5M | 2 companies | $909.5M | Oncology |
| MPM Capital 2 companies · $906.3M | 2 companies | $906.3M | Autoimmune Diseases |
| Omega Funds 2 companies · $895.4M | 2 companies | $895.4M | Oncology |
| Apple Tree Partners 2 companies · $854.5M | 2 companies | $854.5M | Cardiovascular |
| 5AM Ventures 3 companies · $770.8M | 3 companies | $770.8M | Neuromuscular Disorders |
| Innovation Endeavors 2 companies · $638.1M | 2 companies | $638.1M | Oncology |
| Public Shareholders (AIM) 2 companies · $495.6M | 2 companies | $495.6M | Surgery |
| Institutional and public market investors 2 companies · $393.1M | 2 companies | $393.1M | Oncology |
| Novartis Venture Fund 3 companies · $388.6M | 3 companies | $388.6M | Oncology |
| Bpifrance 3 companies · $379.8M | 3 companies | $379.8M | Oncology |
| PIPE Investors 2 companies · $333.1M | 2 companies | $333.1M | Ophthalmology |
| Truffle Capital 2 companies · $324.1M | 2 companies | $324.1M | Cardiovascular Disease |
| Northpond Ventures 2 companies · $259.5M | 2 companies | $259.5M | Neurology |
| Public Shareholders (via NASDAQ IPO) 2 companies · $218.8M | 2 companies | $218.8M | Oncology |
| Baker Brothers Investments 2 companies · $204.3M | 2 companies | $204.3M | Neurology |
| Sofinnova Partners 2 companies · $176.4M | 2 companies | $176.4M | Oncology |
| Oxford Science Enterprises (OSE) 2 companies · $25.7M | 2 companies | $25.7M | Infectious Diseases |
| National Institutes of Health (NIH) 5 companies | 5 companies | — | Neurodegenerative Diseases |
| Menlo Ventures 2 companies | 2 companies | — | Rare Genetic Diseases |
| National Science Foundation (NSF) 2 companies | 2 companies | — | Proteomics |
